Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Obstet Gynecol ; 226(3): 403.e1-403.e13, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34582796

RESUMEN

BACKGROUND: Pregnant women are at an increased risk of mortality and morbidity owing to COVID-19. Many studies have reported on the association of COVID-19 with pregnancy-specific adverse outcomes, but prediction models utilizing large cohorts of pregnant women are still lacking for estimating the risk of maternal morbidity and other adverse events. OBJECTIVE: The main aim of this study was to develop a prediction model to quantify the risk of progression to critical COVID-19 and intensive care unit admission in pregnant women with symptomatic infection. STUDY DESIGN: This was a multicenter retrospective cohort study including 8 hospitals from 4 countries (the United Kingdom, Austria, Greece, and Turkey). The data extraction was from February 2020 until May 2021. Included were consecutive pregnant and early postpartum women (within 10 days of birth); reverse transcriptase polymerase chain reaction confirmed SARS-CoV-2 infection. The primary outcome was progression to critical illness requiring intensive care. The secondary outcomes included maternal death, preeclampsia, and stillbirth. The association between the primary outcome and 12 candidate predictors having a known association with severe COVID-19 in pregnancy was analyzed with log-binomial mixed-effects regression and reported as adjusted risk ratios. All the potential predictors were evaluated in 1 model and only the baseline factors in another. The predictive accuracy was assessed by the area under the receiver operating characteristic curves. RESULTS: Of the 793 pregnant women who were positive for SARS-CoV-2 and were symptomatic, 44 (5.5%) were admitted to intensive care, of whom 10 died (1.3%). The 'mini-COvid Maternal Intensive Therapy' model included the following demographic and clinical variables available at disease onset: maternal age (adjusted risk ratio, 1.45; 95% confidence interval, 1.07-1.95; P=.015); body mass index (adjusted risk ratio, 1.34; 95% confidence interval, 1.06-1.66; P=.010); and diagnosis in the third trimester of pregnancy (adjusted risk ratio, 3.64; 95% confidence interval, 1.78-8.46; P=.001). The optimism-adjusted area under the receiver operating characteristic curve was 0.73. The 'full-COvid Maternal Intensive Therapy' model included body mass index (adjusted risk ratio, 1.39; 95% confidence interval, 1.07-1.95; P=.015), lower respiratory symptoms (adjusted risk ratio, 5.11; 95% confidence interval, 1.81-21.4; P=.007), neutrophil to lymphocyte ratio (adjusted risk ratio, 1.62; 95% confidence interval, 1.36-1.89; P<.001); and serum C-reactive protein (adjusted risk ratio, 1.30; 95% confidence interval, 1.15-1.44; P<.001), with an optimism-adjusted area under the receiver operating characteristic curve of 0.85. Neither model showed signs of a poor fit. Categorization as high-risk by either model was associated with a shorter diagnosis to intensive care unit admission interval (log-rank test P<.001, both), higher maternal death (5.2% vs 0.2%; P<.001), and preeclampsia (5.7% vs 1.0%; P<.001). A spreadsheet calculator is available for risk estimation. CONCLUSION: At presentation with symptomatic COVID-19, pregnant and recently postpartum women can be stratified into high- and low-risk for progression to critical disease, even where resources are limited. This can support the nature and place of care. These models also highlight the independent risk for severe disease associated with obesity and should further emphasize that even in the absence of other comorbidities, vaccination is particularly important for these women. Finally, the model also provides useful information for policy makers when prioritizing national vaccination programs to quickly protect those at the highest risk of critical and fatal COVID-19.


Asunto(s)
COVID-19 , Complicaciones Infecciosas del Embarazo , Femenino , Humanos , Unidades de Cuidados Intensivos , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/epidemiología , Resultado del Embarazo , Mujeres Embarazadas , Estudios Retrospectivos , SARS-CoV-2
2.
Urologia ; 91(2): 419-425, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38156708

RESUMEN

OBJECTIVE: To develop a feasible smartphone urinary diary application (UDA), and evaluate reliability and patient acceptability as a collection, calculation, and sharing tool. MATERIALS AND METHODS: We developed the UDA for smartphones, which collects voiding, leakage, fluid intake, and grade of urgency data. A two-way cross-sectional study was conducted with 60 participants, participants split into two groups. Thirty participants completed UDA for 3 days either preceded or followed by a standard paper diary. We assessed the paper app reliability of the UDA with the Kappa variable and internal correlation coefficient (ICC). RESULTS: 29 (96.6%) participants completed the 3-day UDA in the first phase, 92.6% in the second phase, in comparison to 90% and 79.4% in paper form, respectively. Incomplete variable recording was observed at 10.3%-20% in the UDA group in comparison to 33.3%-34.8 % in the PF group. Of the 48 participants who experienced both diaries, 40 (83.3%) preferred the UDA. Paper app correlation was good to very good with ICC ranging from 0.60 to 0.90 for all variables (p < 0.001). Kappa values for incontinence, stress incontinence, urge incontinence, and increased frequency were 0.95, 0.94, 0.82 0.87, and 0.54; respectively (p < 0.001). CONCLUSION: The performance of developed smartphone UDA is comparable with and highly correlated with paper form with most users finding the app feasible. Convergent validity with urinary incontinence and other lower urinary tract dysfunctions is required.


Asunto(s)
Aplicaciones Móviles , Incontinencia Urinaria , Humanos , Femenino , Estudios Transversales , Persona de Mediana Edad , Incontinencia Urinaria/diagnóstico , Masculino , Diarios como Asunto , Adulto , Reproducibilidad de los Resultados , Anciano , Teléfono Inteligente , Estudios de Factibilidad
3.
Gynecol Oncol Rep ; 49: 101277, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37809349

RESUMEN

Sertoli-Leydig cell tumor (SLCT) is a rare tumor of the ovary.Cushing's syndrome (CS), on the other hand, is a clinical picture formed by the long-term high levels of glucocorticoids in the blood for any reason and the resulting symptoms. Exceptionally in some of cases, a tumor far from the adrenal region synthesizes adrenocortical hormones. Among such ectopic neoplasms, CS Tumors of the ovary that secrete cortisol as a cause of the disease is an exceptional case. In other words, in this case, we argue that the tumor in the ovary causes Cushing's syndrome by secreting cortisol and ACTH-like peptides. There are 5 cases reported in the literature. In this case report we present a case in which SCLT of the ovary was detected by histopathological examination in a patient who underwent laparoscopic surgery due to Cushing's syndrome and bilateral adnexal mass.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA